While soft tissue sarcomas showed a relatively low frequency of MDM2 and CDK4 amplifications, they demonstrated a preliminary trend where wild-type TP53 status correlated with better treatment outcomes. This evidence concerns the gene TP53 and soft tissue sarcoma.